Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H(DE:JIL)
€0.31+0.01 (+4.08%)
DE:JIL
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H financials statements
€0.31
At close:+0.01 (+4.08%)
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H (JIL) Ratios
2 Followers
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H Ratios
DE:JIL's free cash flow for Q2 2026 was ¥0.00. For the 2026 fiscal year, DE:JIL's free cash flow was increased by ¥0.00 and operating cash flow was ¥0.00. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.30 | 1.28 | 1.66 | 2.47 | 1.56 |
| Quick Ratio | 1.22 | 1.21 | 1.51 | 2.29 | 1.41 |
| Cash Ratio | 0.15 | 0.27 | 0.49 | 0.16 | 0.10 |
| Solvency Ratio | 0.23 | 0.23 | 0.21 | 0.30 | 0.28 |
| Operating Cash Flow Ratio | 0.33 | 0.26 | 0.44 | 0.29 | 0.38 |
| Short-Term Operating Cash Flow Coverage | 783.11 | 3.03 | 37.61 | 509.98 | 537.73 |
| Net Current Asset Value | ¥ 240.08M | ¥ 197.56M | ¥ 362.70M | ¥ 1.01B | ¥ 271.31M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.03 | 0.03 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.04 | 0.05 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.04 | 0.05 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.05 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.58 | 1.55 | 1.57 | 1.47 | 1.43 |
| Debt Service Coverage Ratio | 127.93 | 2.87 | 19.77 | 259.57 | 231.86 |
| Interest Coverage Ratio | 154.72 | 103.20 | 386.08 | 414.72 | 516.33 |
| Debt to Market Cap | 0.00 | 0.10 | 0.10 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.13 | 0.14 | 0.00 | 0.00 |
| Net Debt to EBITDA | -0.49 | -0.69 | -1.20 | -0.49 | -0.27 |
| Profitability Margins | |||||
| Gross Profit Margin | 84.01% | 77.77% | 69.40% | 77.00% | 82.22% |
| EBIT Margin | 29.48% | 23.74% | 23.63% | 23.51% | 25.18% |
| EBITDA Margin | 32.62% | 26.82% | 26.90% | 27.50% | 29.27% |
| Operating Profit Margin | 23.80% | 23.74% | 23.63% | 23.51% | 25.18% |
| Pretax Profit Margin | 29.32% | 23.51% | 23.57% | 23.45% | 25.13% |
| Net Profit Margin | 22.05% | 20.91% | 17.61% | 23.00% | 20.31% |
| Continuous Operations Profit Margin | 22.05% | 20.91% | 17.61% | 23.00% | 20.31% |
| Net Income Per EBT | 75.20% | 88.94% | 74.73% | 98.08% | 80.83% |
| EBT Per EBIT | 123.23% | 99.03% | 99.74% | 99.76% | 99.81% |
| Return on Assets (ROA) | 7.45% | 7.28% | 6.39% | 8.16% | 6.91% |
| Return on Equity (ROE) | 11.78% | 11.31% | 10.01% | 12.01% | 9.86% |
| Return on Capital Employed (ROCE) | 12.42% | 12.52% | 12.48% | 11.93% | 11.84% |
| Return on Invested Capital (ROIC) | 9.34% | 10.68% | 9.28% | 11.70% | 9.56% |
| Return on Tangible Assets | 7.59% | 7.44% | 6.41% | 8.35% | 6.94% |
| Earnings Yield | 18.13% | 25.37% | 17.80% | 44.97% | 26.61% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.03 | 2.13 | 2.13 | 1.48 | 1.42 |
| Payables Turnover | 2.33 | 3.08 | 3.65 | 2.95 | 2.44 |
| Inventory Turnover | 1.91 | 3.27 | 2.50 | 1.46 | 1.45 |
| Fixed Asset Turnover | 3.82 | 3.51 | 2.55 | 2.84 | 1.84 |
| Asset Turnover | 0.34 | 0.35 | 0.36 | 0.35 | 0.34 |
| Working Capital Turnover Ratio | 3.48 | 2.47 | 1.10 | 1.23 | 1.99 |
| Cash Conversion Cycle | 213.94 | 164.39 | 217.39 | 373.06 | 358.54 |
| Days of Sales Outstanding | 179.39 | 171.04 | 171.48 | 246.15 | 256.77 |
| Days of Inventory Outstanding | 191.35 | 111.73 | 145.96 | 250.79 | 251.13 |
| Days of Payables Outstanding | 156.81 | 118.38 | 100.05 | 123.87 | 149.36 |
| Operating Cycle | 370.75 | 282.77 | 317.44 | 496.93 | 507.90 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.56 | 0.39 | 0.56 | 0.36 | 0.38 |
| Free Cash Flow Per Share | 0.54 | 0.37 | 0.51 | 0.34 | 0.22 |
| Dividend Paid and CapEx Coverage Ratio | 2.39 | 4.78 | 1.00 | 5.16 | 1.80 |
| Capital Expenditure Coverage Ratio | 25.16 | 19.93 | 9.92 | 18.03 | 2.32 |
| Operating Cash Flow Coverage Ratio | 783.11 | 3.03 | 3.93 | 509.98 | 537.73 |
| Operating Cash Flow to Sales Ratio | 0.35 | 0.25 | 0.38 | 0.24 | 0.30 |
| Free Cash Flow Yield | 27.42% | 28.73% | 34.13% | 44.77% | 22.71% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 5.59 | 3.94 | 5.62 | 2.22 | 3.76 |
| Price-to-Sales (P/S) Ratio | 1.22 | 0.82 | 0.99 | 0.51 | 0.76 |
| Price-to-Book (P/B) Ratio | 0.65 | 0.45 | 0.56 | 0.27 | 0.37 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 3.65 | 3.48 | 2.93 | 2.23 | 4.40 |
| Price-to-Operating Cash Flow Ratio | 3.50 | 3.31 | 2.64 | 2.11 | 2.50 |
| Price-to-Earnings Growth (PEG) Ratio | 0.92 | 0.15 | -0.22 | 0.06 | 0.29 |
| Enterprise Value Multiple | 3.24 | 2.38 | 2.48 | 1.37 | 2.34 |
| Enterprise Value | 954.31M | 562.69M | 560.80M | 317.19M | 483.50M |
| EV to EBITDA | 3.24 | 2.38 | 2.48 | 1.37 | 2.34 |
| EV to Sales | 1.06 | 0.64 | 0.67 | 0.38 | 0.69 |
| EV to Free Cash Flow | 3.17 | 2.70 | 1.97 | 1.65 | 3.95 |
| EV to Operating Cash Flow | 3.05 | 2.56 | 1.77 | 1.55 | 2.25 |
| Tangible Book Value Per Share | 2.92 | 2.81 | 2.63 | 2.78 | 2.58 |
| Shareholders’ Equity Per Share | 3.01 | 2.91 | 2.64 | 2.88 | 2.59 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.25 | 0.11 | 0.25 | 0.02 | 0.19 |
| Revenue Per Share | 1.61 | 1.57 | 1.50 | 1.50 | 1.26 |
| Net Income Per Share | 0.35 | 0.33 | 0.26 | 0.35 | 0.26 |
| Tax Burden | 0.75 | 0.89 | 0.75 | 0.98 | 0.81 |
| Interest Burden | 0.99 | 0.99 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.02 | 0.02 | 0.03 |
| SG&A to Revenue | 0.62 | 0.59 | 0.13 | 0.12 | 0.13 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.18 | 1.06 | 1.59 | 1.03 | 1.21 |
Currency in CNY
